Emerging evidence · Grade B
Cerebrolysin
Cognitive & Neuro
Score
64 / 100
Source
Porcine brain peptides
Route
IV / IM
Status
Used abroad; not FDA-approved
TL;DR
01
A porcine brain-derived mixture of small peptides and amino acids, given by injection/infusion and used for stroke and dementia in many countries (not the US).
02
The best independent evidence is sobering: a Cochrane review of acute ischaemic stroke (7 RCTs, ~1,600 patients) found no benefit on survival and a possible increase in non-fatal serious adverse events.
03
In vascular dementia, a separate Cochrane review found a cognitive signal but concluded there is insufficient evidence to recommend it as routine treatment.
04
Most pivotal trials were supported by the manufacturer, and it is not FDA-approved.
05
So despite wide real-world use, the controlled evidence ranges from unconvincing (dementia) to negative-with-a-safety-flag (stroke).
Stroke (Cochrane)
No survival benefit
7 RCTs · ↑ non-fatal SAEs
Vascular dementia (Cochrane)
Signal, insufficient
6 RCTs · not recommended routine
Trial funding
Mostly manufacturer
independence caveat
FDA
Not approved
used in 50+ countries
Safety flag
↑ non-fatal SAEs
at higher stroke dosing
Part 01 · How it works
Mechanism.
Cerebrolysin is a liquid mixture of small peptides and amino acids extracted from pig brain, proposed to act like the body's own neurotrophic (nerve-growth) factors. The theory is attractive and it's widely used abroad for stroke and dementia. But when the pooled controlled trials are examined independently, the story weakens: for acute stroke, it did not improve survival and may have increased non-fatal serious adverse events; for vascular dementia, there was a cognitive signal but not enough solid evidence to recommend it. Much of the supporting research was funded by the maker.
A 'brain-in-a-bottle' neurotrophic mixture with an appealing rationale and wide use — but when independent reviewers pool the trials, the benefit thins out and a safety flag appears.
Neuropeptide mixture
Low-molecular-weight peptides and free amino acids from porcine brain, proposed to mimic neurotrophic factor activity.
Proposed neuroprotection
Preclinical models suggest neurotrophic, anti-apoptotic, and neuroplastic effects.
Delivery
Given intravenously or intramuscularly in courses, in clinical settings abroad.
Evidence stage
Multiple RCTs; independent Cochrane syntheses find weak-to-absent benefit and a stroke safety signal.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Cerebrolysin has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Clinical course
IV/IM courses
Administered in clinical settings abroad; not an approved US regimen. Higher cumulative doses linked to the SAE signal.
·
Any doses referenced are from clinical use abroad, not US labeling or instructions.
·
Given by injection/infusion in courses under medical supervision where used.
·
The stroke safety signal was more pronounced at higher (300 mL cumulative) dosing.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection/infusion reactions
Local or systemic infusion-related effects.
Occasional
Dizziness / agitation
Reported; generally transient.
Occasional
Serious · rare
Non-fatal serious adverse events (stroke)
Potential increase flagged in the acute-stroke meta-analysis, especially at higher dosing.
Increased (Cochrane)
Porcine-derived product
Animal-derived biologic; theoretical immunogenic/contamination considerations.
Consideration
Absolute · do not use
×
Epilepsy or seizure disorders (may lower seizure threshold)
×
Severe renal impairment
×
Pregnancy or breastfeeding
×
Children under 18 (unless under specialist supervision)
×
Known hypersensitivity to cerebrolysin, porcine-derived products, or any component
Relative · discuss first
!
Reliance on it as a proven stroke therapy — independent evidence does not support benefit
!
Higher-dose regimens — associated with the non-fatal SAE signal
!
Pregnancy or breastfeeding — insufficient data
!
Known sensitivity to porcine-derived products
Interactions
Antidepressants (SSRIs, MAOIs)
Cerebrolysin has neurotrophic effects that may potentiate serotonergic or monoaminergic activity
Moderate
Anticonvulsants
May alter seizure threshold; monitor anticonvulsant levels and seizure frequency
Moderate
Lithium
Both affect neurotrophic signaling (BDNF); theoretical additive or unpredictable CNS effects
Moderate
Cholinesterase inhibitors (donepezil, rivastigmine)
Additive cholinergic effects; may increase side effects but also therapeutic benefit
Minor
Labs to monitor
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function monitoring
CBC with Differential
Baseline and every 3 months
General safety monitoring
Urinalysis
Baseline and monthly
Monitor renal function with parenteral peptide administration
Part 04 · Evidence
How strong is the evidence?
64
Grade B
Grade B, Emerging — but pointed downward by independent evidence. Wide clinical use and many trials, yet Cochrane reviews find insufficient benefit in dementia and no survival benefit (with a non-fatal SAE signal) in stroke, and most pivotal trials are manufacturer-funded.
Mechanistic plausibility
Neurotrophic rationale is plausible but the mixture is poorly defined pharmacologically.
68
Human evidence
Many RCTs, but independent syntheses show weak/absent benefit; large trial base is a genuine plus.
62
Safety & tolerability
Generally tolerated, but the stroke Cochrane review flagged increased non-fatal serious adverse events at higher dosing.
58
Durability
Short treatment courses; durable benefit not established.
58
Independence
Most pivotal trials manufacturer-supported; independent reviews are less favorable.
45
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2020
Cochrane Database Syst Rev Flagged
Cerebrolysin for acute ischaemic stroke (Cochrane review)
Moderate-quality evidence: little or no effect on all-cause death, and a potential increase in non-fatal serious adverse events (RR 2.15) — more pronounced at higher (300 mL cumulative) dosing.
Systematic review/meta-analysis of 7 RCTs · n = 1,601 · Independent Cochrane synthesis; notes manufacturer support of pivotal trials.
PMID 32662068 ↗
High (independent)
02
2013
Cochrane Database Syst Rev Flagged
Cerebrolysin for vascular dementia (Cochrane review)
A beneficial signal on cognition (MMSE, ADAS-cog) and global function, but insufficient evidence to recommend it as routine treatment given few trials, varied durations, and short follow-up.
Systematic review/meta-analysis of 6 RCTs · n = 597 · Independent Cochrane synthesis; signal present but evidence judged insufficient.
PMID 23440834 ↗
High (independent)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
No stroke survival benefit — and a non-fatal serious-adverse-event signal
Safety signal Cochrane Database Syst Rev · 2020
Across 7 RCTs (~1,600 patients), Cerebrolysin had little or no effect on all-cause death in acute ischaemic stroke, and there was a potential increase in non-fatal serious adverse events — more so at higher cumulative doses.
What this means: For its most common serious indication, the best independent evidence shows no survival benefit and a possible harm signal. Wide use is not the same as proven benefit.
PMID 32662068 ↗
02
Dementia benefit is unconfirmed, and trials are mostly manufacturer-funded
Mechanism limit Cochrane Database Syst Rev · 2013
In vascular dementia there was a cognitive signal, but Cochrane concluded the evidence was insufficient to recommend routine use; most pivotal trials were supported by the manufacturer.
What this means: The positive signals should be weighed against limited, industry-linked evidence — not taken as established efficacy.
PMID 23440834 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved
Not FDA-approved; not marketed for clinical use in the US.
N/A / grey-market
European Union
Marketed (varies)
Available in some countries; used for stroke/dementia in clinical settings.
Varies by country
Russia / Asia
Widely used
Common clinical use for stroke and cognitive disorders.
Regional markets
United Kingdom
Not routinely used
Not a routine NHS product.
N/A
The Peptide Column takes no affiliate commission from any source. Cerebrolysin is used clinically in many countries but is not FDA-approved, and independent Cochrane reviews find weak-to-absent benefit with a stroke safety signal. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
What do the large clinical trials (CASTA, CARS) tell us about Cerebrolysin's efficacy for stroke?
02
Why is Cerebrolysin not FDA-approved despite decades of use in other countries?
03
What are the risks of using a porcine-derived biological product?
04
How does Cerebrolysin compare to other neuroprotective strategies for my condition?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Cerebrolysin for acute ischaemic stroke (Cochrane review) · Cochrane Database Syst Rev, 2020 · PMID 32662068 ↗
- 02. Cerebrolysin for vascular dementia (Cochrane review) · Cochrane Database Syst Rev, 2013 · PMID 23440834 ↗
- 03. Cochrane. Cerebrolysin stroke and vascular-dementia systematic reviews